Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.58 |
| ▸ | MRGPRX4 | Q96LA9 | 8/20 | 0.49 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.48 |
| ▸ | SLK | Q9H2G2 | 2/20 | 0.47 |
| ▸ | STK10 | O94804 | 1/20 | 0.47 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.46 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.45 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.44 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.44 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.44 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | PPIA | P62937 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9195885 | 0.88 | MAOB (0.56) | MAOBMRGPRX4SLKSTK10PTGER1 | |
| SCHEMBL20302267 | 0.88 | MAOB (0.58) | MAOBMRGPRX4SLC6A9PTGER1GABRG2 | |
| SCHEMBL224350 | 0.84 | S1PR5 (0.48) | MAOBMRGPRX4PTGER1S1PR5 | |
| SCHEMBL23235823 | 0.83 | MCL1 (0.49) | MAOBALDH1A1 | |
| SCHEMBL1330628 | 0.83 | MAOB (0.62) | MAOBMRGPRX4 | |
| SCHEMBL23541002 | 0.82 | MRGPRX4 (0.44) | MAOBMRGPRX4SLC6A9SLKSTK10 | |
| SCHEMBL15588793 | 0.81 | MAOB (0.46) | MAOBMRGPRX4S1PR5ALDH1A1 | |
| SCHEMBL1980141 | 0.81 | MAOB (0.58) | MAOBMRGPRX4PTGER1GABRG2GABRB3 | |
| SCHEMBL214965 | 0.81 | MAOB (0.58) | MAOBMRGPRX4PTGER1GABRG2GABRB3 | |
| SCHEMBL7129137 | 0.81 | MAOB (0.58) | MAOBMRGPRX4PTGER1GABRG2GABRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118307534-A | LTA4H inhibitors and uses thereof | 上海海雁医药科技有限公司 | 2024-07-09 | — | — | CN | disclosed |
| WO-2023029380-A1 | NOVEL ARYL ETHER SUBSTITUTED HETEROCYCLIC COMPOUND AS GLP1R AGONIST | 杭州德睿智药科技有限公司 | 2023-03-09 | — | — | WO | disclosed |
| US-11161805-B2 | Process for the transition metal catalyzed cyanation of aryl/vinyl halides | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2021-11-02 | — | — | US | disclosed |
| EP-3691784-B1 | PROCESS FOR THE TRANSITION METAL CATALYZED CYANATION OF ARYL/VINYL HALIDES | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2021-09-08 | — | — | EP | disclosed |
| US-20200325099-A1 | PROCESS FOR THE TRANSITION METAL CATALYZED CYANATION OF ARYL/VINYL HALIDES | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2020-10-15 | — | — | US | disclosed |
| CN-102459222-B | L- (piperidin-4-yl) -pyrazole derivatives as GPR119 modulators | PFIZER | 2014-06-04 | — | — | CN | disclosed |
| EP-2643310-A1 | 4- (5-CYANO-PYRAZOL-1-YL) -PIPERIDINE DERIVATIVES AS GPR 119 MODULATORS | Pfizer Inc (US) | 2013-10-02 | — | — | EP | disclosed |
| CN-103298801-A | 4- (5-cyano-pyrazol-1-yl) -piperidine derivatives as GPR 119 modulators | PFIZER | 2013-09-11 | — | — | CN | disclosed |
| WO-2012069948-A1 | 4- (5-CYANO-PYRAZOL-1-YL) -PIPERIDINE DERIVATIVES AS GPR 119 MODULATORS | PFIZER INC. (US) | 2012-05-31 | — | — | WO | disclosed |
| CN-102459222-A | L- (piperidin-4-yl) -pyrazole derivatives as GPR119 modulators | PFIZER | 2012-05-16 | — | — | CN | disclosed |
| EP-2438051-A1 | L- ( PIPERIDIN-4-YL) -PYRAZOLE DERIVATIVES AS GPR 119 MODULATORS | Pfizer Inc. (US) | 2012-04-11 | — | — | EP | disclosed |
| EP-2395835-A1 | AGONISTS AND ANTAGONISTS OF THE SIP5 RECEPTOR, AND METHODS OF USES THEREOF | Abbott Laboratories (US) | 2011-12-21 | — | — | EP | disclosed |
| US-20110020460-A1 | GPR 119 MODULATORS | PFIZER INC. | 2011-01-27 | — | — | US | disclosed |
| WO-2010140092-A1 | L- ( PIPERIDIN-4-YL) -PYRAZOLE DERIVATIVES AS GPR 119 MODULATORS | PFIZER INC. (US) | 2010-12-09 | — | — | WO | disclosed |
| US-20100216762-A1 | Agonists and Antagonists of the S1P5 Receptor, and Methods of Use Thereof | ABBOTT LABORATORIES (US) | 2010-08-26 | — | — | US | disclosed |
| US-20100216762-A1 | Agonists and Antagonists of the S1P5 Receptor, and Methods of Use Thereof | ABBOTT LABORATORIES (US) | 2010-08-26 | — | — | US | disclosed |
| US-20100216762-A1 | Agonists and Antagonists of the S1P5 Receptor, and Methods of Use Thereof | ABBOTT LABORATORIES (US) | 2010-08-26 | — | — | US | disclosed |
| WO-2010093704-A1 | AGONISTS AND ANTAGONISTS OF THE S1P5 RECEPTOR, AND METHODS OF USES THEREOF | ABBOTT LABORATORIES (US) | 2010-08-19 | — | — | WO | disclosed |
| WO-2010093704-A1 | AGONISTS AND ANTAGONISTS OF THE S1P5 RECEPTOR, AND METHODS OF USES THEREOF | ABBOTT LABORATORIES (US) | 2010-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200325099-A1 | PROCESS FOR THE TRANSITION METAL CATALYZED CYANATION OF ARYL/VINYL HALIDES | CYP3A4, CRBN, POR | MAOB 1748/4885MRGPRX4 4463/4885SLC6A9 884/4885 |
| US-20100216762-A1 | Agonists and Antagonists of the S1P5 Receptor, and Methods of Use Thereof | S1PR5, LPAR5, S1PR1 | MAOB 2578/4885MRGPRX4 228/4885SLC6A9 4515/4885 |
| US-20110020460-A1 | GPR 119 MODULATORS | GPR119, GPR65, GPR88 | MAOB 1966/4885MRGPRX4 57/4885SLC6A9 1819/4885 |
| US-11161805-B2 | Process for the transition metal catalyzed cyanation of aryl/vinyl halides | CYP3A4, CRBN, POR | MAOB 1748/4885MRGPRX4 4463/4885SLC6A9 884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.